Prevention of chronic allograft nephropathy with vitamin D

Transplant International

Volumn 18, Issue 10, 2005, Pages 1175-1186

  Hullett, Debra A ^a,c   Laeseke, Paul F ^a   Malin, Gretchen ^a   Nessel, Regina ^b   Sollinger, Hans W ^a   Becker, Bryan N ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c H5/301 CSC ^*  (United States)

Author keywords

Chronic allograft nephropathy; Extracellular matrix; Fibrosis; Transforming growth factor beta; Vitamin D

Indexed keywords

CALCITRIOL; CYCLOSPORIN A; DRUG METABOLITE; GELATINASE A; SMAD2 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; KIDNEY FUNCTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; RAT STRAIN; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CHRONIC DISEASE; CYCLOSPORINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FIBROSIS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MATRIX METALLOPROTEINASES; RATS; RATS, INBRED F344; RATS, INBRED LEW; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD7 PROTEIN; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HOMOLOGOUS; VITAMIN D;

EID: 28444469230     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00187.x     Document Type: Article

References (37)

1. Jain S, Furness PN, Nicholson ML. The role of transforming growth factor beta in chronic renal allograft nephropathy. Transplantation 2000; 69: 1759.
2. Sime PJ, Xing Z, Graham FL, Csaky KG, Gauldie J. Adenovector-mediated gene transfer of active transforming growth factor beta-1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768.
3. Cohen AH, Nast CC. TGF-beta in renal allograft rejection. Miner Electrolyte Metab 1998; 24: 197.
4. Suthanthiran M. Clinical application of molecular biology: a study of allograft rejection with polymerase chain reaction. Am J Med Sci 1997; 313: 264.
5. Shihab FS. Molecular mechanisms of fibrosis in experimental chronic renal allograft injury. Transplantation 1998; 64: 1829.
6. DeLuca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001; 15: 2579.
7. 3. Transplantation 1998; 66: 824.
8. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory t cells induced by lalpha,25-dihydroxyvitamin d(3) and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001; 167: 1945.
9. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A lα,25-dihydroxyvitamin D3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002; 51: 1367.
10. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HFJ, O'Garra A. lα,25-dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974.
11. Strugnell SA, DeLuca HF. The vitamin D receptor-structure and transcriptional activation. Proc Soc Exp Biol Med 1997; 215: 223.
12. Yanagisawa J, Yanagi Y, Masuhiro Y, et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283: 1317.
13. Aschenbrenner JK, Sollinger HW, Becker BN, Hullett DA. 1,25-(OH(2))D(3) alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001; 100: 171.
14. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996; 93: 7861.
15. Diamond JR, Tilney NL, Frye J, et al. Progressive albuminuria and glomerulosclerosis in a rat model of chronic renal allograft rejection. Transplantation 1992; 54: 710.
16. Paul LC. Chronic renal transplant loss. Kidney Int 1995; 47: 1491.
17. Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation 2001; 71: SS5.
18. Tilney NL, Whitley WD, Diamon JR, Kupiec-Weglinski JW, Adams DH. Chronic rejection - an undefined conundrum. Transplantation 1991; 52: 389.
19. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol 2003; 284: F243.
20. Stahl PJ, Felsen D. Transforming growth factor-β, basement membrane, and epithelial-mesenchymal transdifferentiation: implications for fibrosis in kidney disease. Am J Pathol 2001; 159: 1187.
21. Koglin J, Glysing-Jensen T, Raisanen-Sokolowski ARME. Immune sources of transforming growth factor-beta 1 reduce transplant arteriosclerosis: insight derived from a knockout mouse model. Circ Res 1998; 83; 652.
22. Nicholson ML, Bicknell GR, Barker G, Doughman TM, Williams ST, Furness PN. Intragraft expression of transforming growth factor betal gene in isolated glomeruli from human renal transplants. Br J Surg 1999; 86: 1144.
23. Yanagi Y, Suzawa M, Kawabata M, Miyazono K, Yanagisawa J, Kato S. Positive and negative modulation of vitamin D receptor function by transforming growth factor-beta signaling through Smad proteins. J Biol Chem 1999; 274: 12971.
24. 3 and transforming growth factor-beta signalling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem 2001; 276: 15741.
25. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad 7 inhibits fibrotic effect of TGF-β on renal tubular epithelial cells by blocking Smad 2 activation. J Am Soc Nephrol 2002; 13: 1464.
26. Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998; 2: 466.
27. Becker BN, Jacobson LM, Becker YT, et al. Renin-angiotensin system gene expression in post-transplant hypertension predicts allograft function. Transplantation 2000; 69: 1485.
28. Piek E, Ju WJ, Heyer J, et al. Functional characterization of transforming growth factor beta signaling in Smad2-and Smad3-deficient fibroblasts. J Biol Chem 2001; 276: 19945.
29. Darwish HM, DeLuca HF. Recent advances in the molecular biology of vitamin D action. Prog Nucleic Acid Res Mol Biol 1996; 53: 321.
30. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600.
31. Abe H, Iehara N, Utsunomiya K, Kita T, Doi T. A vitamin D analog regulates mesangial cell smooth muscle phenotypes in a transforming growth factor-beta type II receptor-mediated manner. J Biol Chem 1999; 274: 20874.
32. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998; 53: 1696.
33. Kuhlmann A, Haas CS, Gross ML, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526.
34. Chen R, Huang C, Morinelli TA, Trojanowska M, Paul RV. Blockade of the effects of TGF-β1 on mesangial cells by overexpression of Smad7. J Am Soc Nephrol 2002; 13: 887.
35. Bouillon R, Okumura K, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995; 16: 200.
36. van Etten E, Branisteanu DD, Verstuyf A, Waer M, Bouillon R, Mathieu C. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 2000; 69: 1932.
37. Redaelli CA, Wagner M, Gunter-Duwe D, et al. Schilling MK. lalpha,25-dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int 2000; 61: 288.